SCHEMBL14877935

SCHEMBL14877935

CCCCCCC(=O)NCCN1C(=O)C=CC1=O

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 7/20 0.57
PTGS2 P35354 7/20 0.57
FAAH O00519 5/20 0.57
MGLL Q99685 3/20 0.57
DNM1 Q05193 2/20 0.50
CASP2 P42575 1/20 0.49
HSD17B10 Q99714 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17345175 0.94 PTGS1 (0.51) PTGS1PTGS2FAAHMGLLCASP2
SCHEMBL20151750 0.92 MGLL (0.63) FAAHMGLLTRPV1MEN1MAPT
SCHEMBL17740192 0.91 PTGS1 (0.63) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL12146983 0.91 PTGS1 (0.63) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL17740190 0.91 PTGS1 (0.63) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL22295467 0.90 FAAH (0.47) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL15739654 0.90 PTGS1 (0.60) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL19703875 0.90 PTGS1 (0.60) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL19380535 0.90 PTGS1 (0.60) PTGS1PTGS2FAAHMGLLDNM1
SCHEMBL15613431 0.88 PTGS1 (0.57) PTGS1PTGS2FAAHMGLLDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11857638-B2 Quinone-containing conjugates PROMEGA CORPORATION (US) 2024-01-02 US disclosed
US-20220249438-A1 CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS LUNELLA BIOTECH, INC. (CA) 2022-08-11 US disclosed
US-20200030456-A1 QUINONE-CONTAINING CONJUGATES PROMEGA CORPORATION 2020-01-30 US disclosed
US-20170158858-A9 CYANINE COMPOUNDS PIERCE BIOTECHNOLOGY, INC. 2017-06-08 US disclosed
US-20170114038-A9 CYANINE COMPOUNDS PIERCE BIOTECHNOLOGY, INC. 2017-04-27 US disclosed
US-9631096-B2 Dye compositions, methods of preparation, conjugates thereof, and methods of use CORNELL UNIVERSITY (US) 2017-04-25 US disclosed
US-20160176852-A1 CYANINE COMPOUNDS HERMANSON GREG (US) 2016-06-23 US disclosed
US-20160168383-A1 CYANINE COMPOUNDS HERMANSON GREG (US) 2016-06-16 US disclosed
US-20150011731-A1 DYE COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE CORNELL UNIVERSITY (US) 2015-01-08 US disclosed
US-20140255312-A1 CYANINE COMPOUNDS PIERCE BIOTECHNOLOGY, INC. 2014-09-11 US disclosed
US-20140072515-A9 CYANINE COMPOUNDS PIERCE BIOTECHNOLOGY, INC. 2014-03-13 US disclosed
US-20130251637-A9 FLUORESCENT COMPOUNDS DYOMICS GMBH (DE) 2013-09-26 US disclosed
US-20130230466-A1 CYANINE COMPOUNDS HERMANSON GREG (US) 2013-09-05 US disclosed
US-8426618-B2 Luminescence quenching compounds ANASPEC INCORPORATED (US) 2013-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158858-A9 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885
US-20200030456-A1 QUINONE-CONTAINING CONJUGATES NQO1, NQO2, SQOR PTGS1 2095/4885PTGS2 2098/4885FAAH 3232/4885
US-20220249438-A1 CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS UQCRC1, MT-CO2, UQCRC2 PTGS1 2713/4885PTGS2 2501/4885FAAH 4790/4885
US-20140255312-A1 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885
US-20170114038-A9 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885
US-20130230466-A1 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885
US-20160176852-A1 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885
US-20130251637-A9 FLUORESCENT COMPOUNDS NCL, FUS, EFTUD2 PTGS1 4228/4885PTGS2 4278/4885FAAH 3454/4885
US-11857638-B2 Quinone-containing conjugates NQO1, NQO2, SQOR PTGS1 2095/4885PTGS2 2098/4885FAAH 3232/4885
US-20160168383-A1 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885
US-20140072515-A9 CYANINE COMPOUNDS NCL, NOP58, NAT10 PTGS1 4766/4885PTGS2 4738/4885FAAH 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.